These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 7507038)

  • 21. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
    Benfield P; Heel RC; Lewis SP
    Drugs; 1986 Dec; 32(6):481-508. PubMed ID: 2878798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolerability and safety of fluvoxamine and other antidepressants.
    Westenberg HG; Sandner C
    Int J Clin Pract; 2006 Apr; 60(4):482-91. PubMed ID: 16620364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluvoxamine: an antidepressant for the elderly?
    Kellett JM
    J Psychiatry Neurosci; 1991 Jul; 16(2 Suppl 1):26-9. PubMed ID: 1931933
    [No Abstract]   [Full Text] [Related]  

  • 24. The elderly depressed and treatment with fluvoxamine.
    Phanjoo A
    Int Clin Psychopharmacol; 1991 Dec; 6 Suppl 3():33-7; discussion 37-9. PubMed ID: 1806633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind, randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients.
    Rahman MK; Akhtar MJ; Savla NC; Sharma RR; Kellett JM; Ashford JJ
    Br J Clin Pract; 1991; 45(4):255-8. PubMed ID: 1810358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Notes on the use of fluvoxamine as treatment of depression in HIV-1-infected subjects.
    Grassi B; Gambini O; Scarone S
    Pharmacopsychiatry; 1995 May; 28(3):93-4. PubMed ID: 7568371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness.
    Harris MG; Benfield P
    Drugs Aging; 1995 Jan; 6(1):64-84. PubMed ID: 7696780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.
    Davis R; Whittington R; Bryson HM
    Drugs; 1997 Apr; 53(4):608-36. PubMed ID: 9098663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction between fluvoxamine and imipramine/desipramine in four patients.
    Spina E; Campo GM; Avenoso A; Pollicino MA; Caputi AP
    Ther Drug Monit; 1992 Jun; 14(3):194-6. PubMed ID: 1412604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluvoxamine: a review of its therapeutic potential in the management of anxiety disorders in children and adolescents.
    Cheer SM; Figgitt DP
    Paediatr Drugs; 2001; 3(10):763-81. PubMed ID: 11706925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluvoxamine. A review of its safety profile in world-wide studies.
    Wagner W; Zaborny BA; Gray TE
    Int Clin Psychopharmacol; 1994; 9(4):223-7. PubMed ID: 7868844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A risk-benefit assessment of mirtazapine in the treatment of depression.
    Kasper S; Praschak-Rieder N; Tauscher J; Wolf R
    Drug Saf; 1997 Oct; 17(4):251-64. PubMed ID: 9352961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance.
    Leonard BE
    Drugs; 1992; 43 Suppl 2():3-9; discussion 9-10. PubMed ID: 1378371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders.
    Haria M; Fitton A; McTavish D
    Drugs Aging; 1994 Apr; 4(4):331-55. PubMed ID: 8019056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of fluvoxamine in severe depression.
    Mendlewicz J
    Drugs; 1992; 43 Suppl 2():32-7; discussion 37-9. PubMed ID: 1378372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression.
    Wilde MI; Benfield P
    Drugs; 1995 Mar; 49(3):411-39. PubMed ID: 7774514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mirtazapine: a review of its use in major depression.
    Holm KJ; Markham A
    Drugs; 1999 Apr; 57(4):607-31. PubMed ID: 10235695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy.
    Holliday SM; Plosker GL
    Drugs Aging; 1993; 3(3):278-99. PubMed ID: 8324301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spotlight on fluvoxamine in anxiety disorders in children and adolescents.
    Cheer SM; Figgitt DP
    CNS Drugs; 2002; 16(2):139-44. PubMed ID: 11825104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder.
    McTavish D; Benfield P
    Drugs; 1990 Jan; 39(1):136-53. PubMed ID: 2178909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.